Non-Exudative Age-Related Macular Degeneration (Dry AMD)

Sponsor – Genentech/Roche (Closed to Enrollment)

CHROMA – Geographic Atrophy (GA)
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/results?term=CHROMA&Search=Search

Previous Dry AMD Studies:

Principal Investigator, 2013 - 2013
A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-04382923) in Subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration